Docusign Envelope ID: 9935B39E-66CD-84C3-80B1-B2D360FE6CC4

GENERALFORSAMLINGSPROTOKOLLAT

DANISH BIO - DANSK BIOTEK

MINUTES OF ANNUAL GENERAL MEETING

DANISH BIO - DANSK BIOTEK

Docusign Envelope ID: 9935B39E-66CD-84C3-80B1-B2D360FE6CC4

GENERALFORSAMLINGSPROTOKOLLAT

ORDINÆR GENERALFORSAMLING

DATO: 21. MAJ 2026

DANISH BIO - DANSK BIOTEK

CVR-NR. 28 43 65 72

Dags dato afholdtes ordinær generalforsamling i DANISH BIO - DANSK BIOTEK, CVR-nr. 28 43 65 72 ("**Foreningen**"), på adressen Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 København Ø.

Dagsordenen var som følger:

a) Valg af dirigent

b) Formandens beretning

c) Godkendelse af regnskab for 2025

d) Fastsættelse af kontingent for 2027

e) Valg af formand

f) Valg af medlemmer til bestyrelsen

g) Valg af revisor

h) Behandling af forslag

i) Eventuelt

Ad a)

Til dirigent valgtes advokat Thomas Holst Laursen, Plesner Advokatpartnerselskab, der konstaterede, at generalforsamlingen var lovligt indkaldt og beslutningsdygtig i forhold til punkterne på dagsordenen.

Ad b)

Bestyrelsesformand Hans Schambye aflagde sin beretning om Foreningens aktiviteter i det forgangne regnskabsår.

Generalforsamlingen tog formandens beretning til efterretning.

MINUTES OF ANNUAL GENERAL MEETING

ANNUAL GENERAL MEETING

DATE: 21 MAY 2026

DANISH BIO - DANSK BIOTEK

CVR NO. 28 43 65 72

Today the Annual General Meeting of DANISH BIO - DANSK BIOTEK, CVR no. 28 43 65 72 (the "**Association**"), was held at Plesner Advokatpartnerselskab, Amerika Plads 37, DK-2100 Copenhagen

The agenda was as follows:

a) Election of Chairman of the Annual General Meeting

b) Chairman's statement

c) Approval of financial result for 2025

d) Determination of membership fees for 2027

e) Election of Chairman

f) Election of Members of the Board

g) Election of Auditor

h) Discussion of proposals

i) Any other business

Re a)

Attorney-at-law, Thomas Holst Laursen, Plesner Advokatpartnerselskab, was elected Chairman of the general meeting. The Chairman of the general meeting ascertained that the general meeting was legally convened and constituted a quorum in relation to all items on the agenda.

Re b)

The Chairman of the Board, Hans Schambye, gave his statement on the activities of the Association during the past accounting year.

The general meeting took due notice of the Chairman of the Board's statement.

Docusign Envelope ID: 9935B39E-66CD-84C3-80B1-B2D360FE6CC4

Ad c)

Årsregnskab med revisionspåtegning for 2025 blev fremlagt til generalforsamlingens godkendelse.

Foreningens årsrapport blev enstemmigt og med alle stemmer godkendt af generalforsamlingen.

Re c)

The annual report with the auditor's report for 2025 was presented for the general meeting's approval.

The annual report of the Association was unanimously and with all votes approved by the general meeting.

Ad d)

Der forelå forslag om, at kontingent for 2027 skulle fastsættes uændret i forhold til 2026.

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

I overensstemmelse hermed fastsattes kontingentet for 2027 som følger:

Start-ups

- Biotek start-ups (indtil kapital på DKK 10 mio. er rejst): Gratis

Offentlige interessemedlemmer og små virksomhedsmedlemmer

- DKK 5.000

Lægemiddel & industriel biotek/Pharma + investorer

- Mindre end 10 ansatte: DKK 5.000
- Mellem 10-200 ansatte: DKK 15.000
- Mere end 200 ansatte: DKK 35.000
- Mere end 1,000 ansatte: DKK 50.000

Associerede medlemmer

- Mindre end 10 ansatte: DKK 15.000
- Mellem 10-200 ansatte: DKK 20.000
- Mere end 200 ansatte: DKK 40.000

Medlemmer med udenlandsk hjemsted

- Halv pris på medlemskontingentet for den relevante medlemskategori

Re d)

A proposal was submitted that the membership fees for 2027 should remain unchanged compared to 2026.

The proposal was unanimously and with all votes approved by the general meeting.

Accordingly, the membership fees for 2027 were determined as follows:

Start-ups

- Biotech start-ups (until DKK 10 million in capital has been raised): Free

Public members and small entity members

- DKK 5,000

Medical & Industrial Biotech/Pharma + Investors

- Less than 10 employees: DKK 5,000
- Between 10-200 employees: DKK 15,000
- More than 200 employees: DKK 35,000
- More than 1,000 employees: DKK 50,000

Associated members

- Less than 10 employees: DKK 15,000
- Between 10-200 employees: DKK 20,000
- More than 200 employees: DKK 40,000

Members with foreign domicile

- Half price of membership fee for the relevant membership category

Ad e)

Det blev oplyst, at bestyrelsesformanden vælges for en toårig periode og kan genvælges.

Hans Schambye (2025-2027) fortsætter som bestyrelsesformand i henhold til hans eksisterende valgperiode.

Generalforsamlingen tog dette til efterretning.

Re e)

It was informed that the Chairman of the Board is elected for a two-year period and may be re-elected.

Hans Schambye (2025-2027) continues as Chairman of the Board in accordance with his current election period.

The general meeting took due notice of this.

Docusign Envelope ID: 9935B39E-66CD-84C3-80B1-B2D360FE6CC4

Ad f)

Det blev oplyst, at bestyrelsen vælges for en toårig periode og kan genvælges.

Hans Schambye, Henrik Blou, Lone Dybdal Nilsson, Søren Møller og Lasse Nørregaard fortsætter som bestyrelsesmedlemmer i henhold til deres eksisterende valgperioder (2025-2027).

Der forelå forslag om genvalg af Jørgen Godt Olsen og Thomas Kongstad Petersen som bestyrelsesmedlemmer.

Der forelå desuden forslag om at vælge Trine Bartholdy som nyt medlem af bestyrelsen.

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

Bestyrelsen består herefter af følgende medlemmer:

- Hans Schambye, CEO, Boost Pharma ApS (Chairman) (2025-2027)
- Henrik Blou, CEO, Gubra (2025-2027)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2025-2027)
- Søren Møller, Managing Partner, Novo Holdings A/S (2025-2027)
- Lasse Nørregaard, Chief Business Officer, XY Therapeutics, Loma Therapeutics, Probmet Therapeutics (2025-2027)
- Jørgen Godt Olsen, Executive Vice President, Niels Clauson-Kaas (2026-2028)
- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2026-2028)
- Trine Bartholdy, Chief Business Officer, Bio-Innovation Institute (2026-2028)

Re f)

It was informed that the Board is elected for a two-year period and may be re-elected.

Hans Schambye, Henrik Blou, Lone Dybdal Nilsson, Søren Møller and Lasse Nørregaard will continue as members of the Board in accordance with their current election periods (2025-2027).

A proposal was submitted to re-elect Jørgen Godt Olsen and Thomas Kongstad Petersen as members of the Board.

Further, a proposal was submitted to elect Trine Bartholdy as a new member of the Board.

The proposal was unanimously and with all votes approved by the general meeting.

Accordingly, the members of the Board are the following:

- Hans Schambye, CEO, Boost Pharma ApS (Chairman) (2025-2027)
- Henrik Blou, CEO, Gubra (2025-2027)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2025-2027)
- Søren Møller, Managing Partner, Novo Holdings A/S (2025-2027)
- Lasse Nørregaard, Chief Business Officer, XY Therapeutics, Loma Therapeutics, Probmet Therapeutics (2025-2027)
- Jørgen Godt Olsen, Executive Vice President, Niels Clauson-Kaas (2026-2028)
- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2026-2028)
- Trine Bartholdy, Chief Business Officer, Bio-Innovation Institute (2026-2028)

Ad g)

Der forelå forslag om genvalg af EY Godkendt Revisionspartnerselskab, CVR-nr. 30 70 02 28, som Foreningens revisor.

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

Re g)

A proposal to re-elect EY Revisionspartnerselskab, CVR no. 30 70 02 28, as the Association's auditor was submitted.

The proposal was unanimously and with all votes approved by the general meeting.

Ad h)

Re h)

Docusign Envelope ID: 9935B39E-66CD-84C3-80B1-B2D360FE6CC4

Der forelå ingen indkomne forslag.

No proposals were received for discussion.

Ad i)

Der var ingen bemærkninger under dette punkt.

Re i)

There were no comments under this item.

- 0 -

- 0 -

Generalforsamlingen hævet.

The general meeting adjourned.

Som dirigent / As Chairman of the Annual General Meeting:

Signed by:
24BEEB6032DF4EC...

Thomas Holst Laursen